IO Biotech Faces Delisting Concerns
Ticker: IOBT · Form: 8-K · Filed: Dec 19, 2025 · CIK: 1865494
| Field | Detail |
|---|---|
| Company | Io Biotech, Inc. (IOBT) |
| Form Type | 8-K |
| Filed Date | Dec 19, 2025 |
| Risk Level | high |
| Pages | 3 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001, $1.00 |
| Sentiment | bearish |
Sentiment: bearish
Topics: delisting, listing-standards, regulatory
TL;DR
IO Biotech might get kicked off the exchange.
AI Summary
IO Biotech, Inc. filed an 8-K on December 19, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard. The company, incorporated in Delaware with its principal executive offices in Copenhagen, Denmark, is subject to this filing as of December 17, 2025.
Why It Matters
This filing indicates potential issues with IO Biotech's compliance with stock exchange listing requirements, which could lead to its shares being delisted.
Risk Assessment
Risk Level: high — A notice of delisting or failure to meet listing standards poses a significant risk to the company's stock trading status and investor confidence.
Key Numbers
- 001-41008 — SEC File Number (Identifies the company's filings with the SEC.)
- 87-0909276 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- IO Biotech, Inc. (company) — Registrant
- December 17, 2025 (date) — Earliest event reported
- December 19, 2025 (date) — Filing date
- Delaware (jurisdiction) — State of Incorporation
- Copenhagen, Denmark (location) — Principal Executive Offices
FAQ
What specific listing rule or standard has IO Biotech, Inc. failed to satisfy?
The filing does not specify the exact rule or standard that IO Biotech, Inc. has failed to satisfy, only that a notice of delisting or failure to satisfy a continued listing rule or standard has been issued.
What is the earliest event date reported in this 8-K filing?
The earliest event date reported is December 17, 2025.
When was this 8-K form filed with the SEC?
This 8-K form was filed on December 19, 2025.
Where are IO Biotech, Inc.'s principal executive offices located?
IO Biotech, Inc.'s principal executive offices are located at Ole Maaløes Vej 3, DK-2200 Copenhagen N, Denmark.
What is the company's SEC file number?
The company's SEC file number is 001-41008.
Filing Stats: 782 words · 3 min read · ~3 pages · Grade level 13.4 · Accepted 2025-12-19 17:18:23
Key Financial Figures
- $0.001 — ange on which registered Common Stock, $0.001 par value per share IOBT The Nasdaq
- $1.00 — Company's common stock had fallen below $1.00 per share for 30 consecutive trading da
Filing Documents
- d71494d8k.htm (8-K) — 23KB
- 0001193125-25-327089.txt ( ) — 135KB
- iobt-20251217.xsd (EX-101.SCH) — 3KB
- iobt-20251217_lab.xml (EX-101.LAB) — 17KB
- iobt-20251217_pre.xml (EX-101.PRE) — 11KB
- d71494d8k_htm.xml (XML) — 4KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IO Biotech, Inc. Date: December 19, 2025 By: /s/ Mai-Britt Zocca Mai-Britt Zocca, Ph.D. Chief Executive Officer